The European Journal of Immunology (EJI) is an official journal of EFIS. Established in 1971, EJI continues to serve the needs of the global immunology community covering basic, translational and clinical research, ranging from adaptive and innate immunity through to vaccines and immunotherapy, cancer, autoimmunity, allergy and more.

Mechanistic insights and thought-provoking immunological findings are of interest, as are studies using the latest omics technologies. We offer fast track review for competitive situations, including recently scooped papers, format free submission, transparent and fair peer review and more as detailed in our policies.

Highlights

Skip slideshow

Articles

Technical Report
Open access

Highly sensitive reporter cell line for detection of interferon types I–III and their neutralization by antibodies

  •  4 October 2024

Graphical Abstract

Highly sensitive reporter cell line for detection of interferon types I–III and their neutralization by antibodies Issue ,

Interferons (IFNs) are a critical component of innate immune defenses and limit viral disease severity. To advance studies on IFNs and their neutralization by pathogenic autoantibodies, we generated a Renilla luciferase-based reporter cell line capable of detecting the activities of IFN-Is, IFN-II, and IFN-IIIs. The reporter cell line exhibits a 125- to 2000-fold higher sensitivity to IFNs than a commonly used alternative biological reporter system and allows for a rapid and simple live-cell workflow for detecting low titer amounts of neutralizing anti-IFN antibodies.

Cover Picture
free access

Cover Story: Eur. J. Immunol. 10'24

  •  4 October 2024

Graphical Abstract

Cover Story: Eur. J. Immunol. 10'24 Issue 10, 2024

Our cover features images related to flow cytometry techniques widely used for analysis of function and phenotypes of major human and murine immune cell subsets, superimposed on a multidimensional immune cell population scatter plot. These images are taken from the third edition of EJI's Flow Cytometry Guidelines by Cossarizza et al., a comprehensive resource prepared by flow cytometry and immunology research experts from around the world.

Impressum

Impressum

  •  4 October 2024
Research Article|Basic

A20 intrinsically influences human effector T‐cell survival and function by regulating both NF‐κB and JNK signaling

  •  2 October 2024

Graphical Abstract

A20 intrinsically influences human effector T-cell survival and function by regulating both NF-κB and JNK signaling Issue ,

The ubiquitin-editing enzyme A20 regulates innate and adaptive immune receptor signaling, but its intrinsic function in human T cells is poorly understood. We show that A20 deletion enhances cytokine secretion and alters apoptosis sensitivity in primary human T cells by modulating NF-kB and JNK/AP-1 signaling downstream of the CARD11-BCL10-MALT1 complex.

Research Article|Basic

Liver type 1 innate lymphoid cells undergo apoptosis in murine models of macrophage activation syndrome and are dispensable for disease

  •  30 September 2024

Graphical Abstract

Liver type 1 innate lymphoid cells undergo apoptosis in murine models of macrophage activation syndrome and are dispensable for disease Issue ,

In macrophage activation syndrome, a severe cytokine storm syndrome with liver inflammation, liver type 1 innate lymphoid cells (ILC1s) rapidly produce proinflammatory cytokines. However, disease progression results in liver ILC1 apoptosis. In addition, disease development was unaltered in Hobit knockout mice, which lack liver ILC1s, indicating their dispensability for disease.

More articles

The following is a list of the most cited articles based on citations published in the last three years, according to CrossRef.

free access

CD69: from activation marker to metabolic gatekeeper

  •  946-953
  •  5 May 2017

Graphical Abstract

CD69: from activation marker to metabolic gatekeeper Issue 6, 2017

CD69 associates to LAT1 and controls its plasma membrane expression and amino acid transporter activity in T lymphocytes.

free access

Targeting Treg cells in cancer immunotherapy

  •  1140-1146
  •  30 June 2019

Graphical Abstract

Targeting Treg cells in cancer immunotherapy Issue 8, 2019

Regulatory T (Treg) cells highly infiltrate into various tumor tissues and hinder immune responses against tumor cells by effector T (Teff) cells. To effectively enhance anti-tumor immunity, it is essential to selectively remove tumor-infiltrating Treg cells while preserving tumor-reactive Teff cells.

More articles

Latest news